Skip to main content
Caplight Logo









Tallac Therapeutics

Tallac Therapeutics

Private
Burlingame, CaliforniaHealthcare & Life Scienceshttps://www.tallactherapeutics.com/

Last Round

Debt

Jul 31, 2023

Total Funding Raised

$67M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Tallac Therapeutics is a biopharmaceutical company that develops antibody-oligonucleotide conjugates to harness innate and adaptive immunity for the treatment of cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

immunotherapyantibody conjugateTLR9 agonistoncologysolid tumorbiotechToll-like receptorTLRdrug developmentclinical trialtargeted therapybiopharmainvestigational new drugINDADCcancer drug

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Tallac Therapeutics Comparables

Compare Tallac Therapeutics with similar companies based on industry and business-model similarity.

Tallac Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Bolt Biotherapeutics
81%
ARS Pharmaceuticals
78%
Canwell Biotech Ltd.
73%

Tallac Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
DebtJul 31, 2023
Series ADec 1, 2020

Key People

Founding team and executive leadership

Hong I. Wan

President, Chief Executive Officer and Co-Founder

Founding Team

Tallac Therapeutics Investors

Notable investors and investment history

Tallac Therapeutics investors
InvestorRounds
MatrixSeries A
Lightstone VenturesSeries A
Morningside VenturesSeries A
MPCSeries A
Horizon Technology Finance CorporationDebt
venBioSeries A
Morningside GroupSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 27, 2026

    Monthly visitors grew 38% MoM, reaching 1.9K.

  • May 16, 2026

    Monthly visitors increased 194% MoM, reaching 2.4K.

Tallac Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Tallac Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Tallac Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBurlingame, California
Employee Range12
Year Founded2018
Last FundingJul 31, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?